Savara (SVRA) Preferred Stock Liabilities (2014 - 2016)
Savara (SVRA) reported Preferred Stock Liabilities of $43.9 million for Q4 2016, up 2.04% year-over-year from $43.0 million in Q1 2016, and up 2.04% on a QoQ basis from $43.0 million in Q4 2015.
Savara (SVRA) has 3 years of Preferred Stock Liabilities data on file, last reported at $43.9 million in Q4 2016.
- Quarterly Preferred Stock Liabilities rose 2.04% year-over-year to $43.9 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $43.9 million (up 2.04% YoY) and the FY2016 annual result came in at $43.9 million, up 2.04% from the prior year.
- Preferred Stock Liabilities rose to $43.9 million in Q4 2016 per SVRA's latest filing, from $43.0 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $43.9 million in Q4 2016 and bottomed at $20.3 million in Q4 2014.
- The 3-year median for Preferred Stock Liabilities is $43.0 million (2015), against an average of $35.7 million.
- The widest annual swing landed in 2015, when Preferred Stock Liabilities jumped 112.05%; it then increased 2.04% in 2016.
- Tracing SVRA's Preferred Stock Liabilities over 3 years: stood at $20.3 million in 2014, then surged by 112.05% to $43.0 million in 2015, then grew by 2.04% to $43.9 million in 2016.
- Per Business Quant, the three latest SVRA Preferred Stock Liabilities figures stand at $43.9 million (Q4 2016), $43.0 million (Q4 2015), and $20.3 million (Q4 2014).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 43.86 Mn |
| Dec 31, 2015 | 42.99 Mn |
| Dec 31, 2014 | 20.27 Mn |